Invasive candidiasis remains one of the most prevalent systemic mycoses, and several studies have documented the presence of mixed yeast (MY) infections. Here, we describe the epi-demiology, clinical, and microbiological characteristics of MY infections causing invasive candidiasis in a multicenter prospective study. Thirty-four centers from 14 countries participated. Samples were collected in each center between April to September 2018, and they were sent to a reference center to confirm identification by sequencing methods and to perform antifungal susceptibility testing, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). A total of 6895 yeast cultures were identified and MY occurred in 150 cases (2.2%). Europe ac-counted for the highest number of centers, with an overall MY rate of 4.2% (118 out of 2840 yeast cultures). Of 122 MY cases, the most frequent combinations were Candida albicans/C. glabrata (42, 34.4%), C. albicans/C. parapsilosis (17, 14%), and C. glabrata/C. tropicalis (8, 6.5%). All Candida isolates were susceptible to amphotericin B, 6.4% were fluconazole-resistant, and two isolates (1.6%) were echinocandin-resistant. Accurate identification of the species involved in MY infections is essential to guide treatment decisions.
Mixinyeast: A multicenter study on mixed yeast infections / Medina, N.; Soto-Debran, J. C.; Seidel, D.; Akyar, I.; Badali, H.; Barac, A.; Bretagne, S.; Cag, Y.; Cassagne, C.; Castro, C.; Chakrabarti, A.; Dannaoui, E.; Cardozo, C.; Garcia-Rodriguez, J.; Guitard, J.; Hamal, P.; Hoenigl, M.; Jagielski, T.; Khodavaisy, S.; Lo Cascio, G.; Martinez-Rubio, M. C.; Meletiadis, J.; Munoz, P.; Ochman, E.; Pelaez, T.; Balzola, A. P. -A.; Prattes, J.; Roilides, E.; de Pipaon, M. R. -P.; Stauf, R.; Steinmann, J.; Suarez-Barrenechea, A. I.; Tejero, R.; Trovato, L.; Vinuela, L.; Wongsuk, T.; Zak, I.; Zarrinfar, H.; Lass-Florl, C.; Arikan-Akdagli, S.; Alastruey-Izquierdo, A.. - In: JOURNAL OF FUNGI. - ISSN 2309-608X. - 7:1(2021), pp. 13.1-13.14. [10.3390/jof7010013]
Mixinyeast: A multicenter study on mixed yeast infections
Lo Cascio G.;
2021-01-01
Abstract
Invasive candidiasis remains one of the most prevalent systemic mycoses, and several studies have documented the presence of mixed yeast (MY) infections. Here, we describe the epi-demiology, clinical, and microbiological characteristics of MY infections causing invasive candidiasis in a multicenter prospective study. Thirty-four centers from 14 countries participated. Samples were collected in each center between April to September 2018, and they were sent to a reference center to confirm identification by sequencing methods and to perform antifungal susceptibility testing, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). A total of 6895 yeast cultures were identified and MY occurred in 150 cases (2.2%). Europe ac-counted for the highest number of centers, with an overall MY rate of 4.2% (118 out of 2840 yeast cultures). Of 122 MY cases, the most frequent combinations were Candida albicans/C. glabrata (42, 34.4%), C. albicans/C. parapsilosis (17, 14%), and C. glabrata/C. tropicalis (8, 6.5%). All Candida isolates were susceptible to amphotericin B, 6.4% were fluconazole-resistant, and two isolates (1.6%) were echinocandin-resistant. Accurate identification of the species involved in MY infections is essential to guide treatment decisions.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
